GSK plc (LON:GSK) Receives GBX 1,805.83 Average PT from Brokerages

GSK plc (LON:GSK) has earned a consensus recommendation of “Moderate Buy” from the seven research firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price target among analysts that have covered the stock in the last year is GBX 1,805.83 ($24.05).

Separately, JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of GSK in a research report on Friday, March 28th.

Insiders Place Their Bets

In other news, insider Wendy Becker acquired 536 shares of GSK stock in a transaction on Thursday, March 20th. The stock was acquired at an average cost of GBX 1,515 ($20.17) per share, with a total value of £8,120.40 ($10,812.78). Also, insider Emma Walmsley sold 38,459 shares of the firm’s stock in a transaction on Monday, February 17th. The stock was sold at an average price of GBX 1,418 ($18.88), for a total value of £545,348.62 ($726,163.28). Insiders own 1.61% of the company’s stock.

GSK Trading Down 0.4 %

Shares of GSK stock opened at GBX 1,389 ($18.50) on Thursday. The company has a market cap of £56.36 billion, a P/E ratio of 22.44, a PEG ratio of 1.24 and a beta of 0.31. GSK has a fifty-two week low of GBX 1,242.50 ($16.54) and a fifty-two week high of GBX 1,823.50 ($24.28). The stock has a 50 day simple moving average of GBX 1,432.59 and a two-hundred day simple moving average of GBX 1,401.37. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81.

GSK (LON:GSK) last posted its quarterly earnings results on Wednesday, February 5th. The company reported GBX 23.20 ($0.31) EPS for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. Research analysts forecast that GSK will post 175.980975 earnings per share for the current year.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.